We report two novel mutations in the splice sites of BRCA1 exon 5: IVS5+3A4G, a Belgian founder mutation, and IVS376T4G, identi®ed in one family with a strong family history of breast cancer. Real-time RT ± PCR showed that IVS376T4G leads to a ®vefold increase of the BRCA1-Dex5 (isoform with an in frame skip of exon 5) ratio to the total BRCA1 expression level. IVS5+3A4G results in a 10-fold increase of the BRCA1-D22ntex5 ratio (isoform with an out of frame skip of the last 22 nucleotides of exon 5) and a twofold increase of the BRCA1-Dex5 ratio. These altered ratios are most likely to result from increased expression of the alternative transcripts, although we cannot completely rule out a small decrease of the total BRCA1 expression level due to highly variable BRCA1 levels in cultured cell lines. In order to explore the functional signi®cance of the isoforms, we evaluated their prevalence in normal tissues and cancer cell lines. The BRCA1-D22ntex5 ratio was signi®cantly higher in an ovarian cancer cell line compared to normal ovarian tissue. Our ®ndings suggest that revealing the defects caused by some splice mutations requires accurate quantitative methods. We hypothesize that disruption of alternative transcript ratios of BRCA1 may be a dominant mechanism aecting predisposition to hereditary breast and/or ovarian cancer. Oncogene (2002) 21, 4171 ± 4175. doi:10.1038/sj.onc. 1205520
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Keywords: BRCA1; splice mutation; real time RT ± PCR; breast cancer By extensive linkage studies on families with a strong predisposition for breast and/or ovarian cancer and by positional cloning BRCA1 was mapped to 17q21 and BRCA2 to 13q12.3 (Easton et al., 1993; Miki et al., 1994; Wooster et al., 1995) . A large number of dierent mutations in BRCA1 and BRCA2 implicated in the familial occurrence of breast and/or ovarian cancer, have been described in many pedigrees. In the BIC (Breast Information Core) database (http:// www. nhgri.nih.gov/Intramural_research / Lab_transfer/ Bic/Member/) splicing mutations only account for 7% of the germline mutations reported in BRCA1 and for 5% in BRCA2. In this study we report two novel splice site mutations outside the highly conserved 3' AG-acceptor (IVS376T4G) and 5' GT-donor (IVS5+3A4G) of exon 5 of the BRCA1 gene and showed how both mutations exert their pathological eect.
Both mutations were identi®ed by DGGE (denaturing gradient gel electrophoresis) on gDNA. IVS5+3A4G was identi®ed in nine apparently unrelated families and is a Belgian founder mutation (Claes et al., 1999, Claes et al., manuscript in preparation) . IVS376T4G was detected in a proband diagnosed with breast cancer at age 43, who developed a second cancer in the same breast at age 46 years. Her sister developed a brain tumor at age 40 and is also carrying the mutation. Both inherited the mutation from their father. Several other family members in the paternal branch of the family have been diagnosed with breast cancer. Unfortunately, these patients were not available for further study.
In all patients the complete coding region of both BRCA1 and BRCA2 was analysed by DGGE and no other mutation was found. In none of 100 unrelated healthy control persons IVS5+3A4G or IVS376T4G was detected, underscoring that these variants are very unlikely to represent polymorphic alterations in our population.
In order to interprete the pathogenic eect of these variants, BRCA1 mRNA expression studies, including the search for alternative transcripts, were initiated.
Fragment analysis of RT ± PCR products spanning exons 2 ± 7 showed that two alternative transcripts were more prevalent in patients carrying IVS5+3A4G than in controls (Figure 1 ): a transcript 22 nucleotides shorter than the full length fragment, containing an out of frame skip of the last 22 nucleotides of exon 5 (BRCA1-D22ntex5) and a transcript 78 basepairs shorter than the full length transcript, representing an in frame skip of exon 5 (BRCA1-Dex5). Although both A and G are consensus nucleotides at the +3 position of splice donor sites, with A found in 42% and G in 52% of the mammalian genes (Shapiro and Senapathy, 1987) , Ohno et al. (1999) showed that the presence of a G at nucleotide +3 is associated with preferential usage of nucleotides concordant with U1 snRNA at position +4 to +6 of the 5' splice site. They concluded that with G at +3 normal splicing depends on the concordance of residues +4 to +6 with U1 snRNA. In the donor site of BRCA1 exon 5 [AAG||gt(a4g)tat] nucleotides +4 and +5 are not concordant with the consensus sequence [(A/C)AG||gt(a/g)agt] and therefore aberrant splicing is induced by IVS5+3A4G. The Splice Site Prediction program using Neural Networks (SSPNN) (http://www.fruit¯y.org/seq_tools/splice.html) calculates a score of 0.92 for the wild-type donor of exon 5. IVS5+3A4G lowers the donor consensus value to 0.53, leading to preferential usage of a cryptic donor present in exon 5 with a score of 0.91 [TAT||gtaaga] . This results in an out of frame skip of the last 22 nucleotides of exon 5, creating a premature stop codon (Stop 64). In control persons this shorter transcript is also observed but at a much lower level as evidenced by the much smaller peak height.
The main eect of IVS376T4G is skipping (in frame) of exon 5 as shown by fragment analysis (Figure 1 ). This mutation inserts an extra purine in the polypyrimidine tract of the acceptor site of exon 5 (tttataat(t4g)tatag||A; consensus sequence: tyttytytyyyyncag||G) and the score for the acceptor sequence of exon 5 is hereby reduced from 0.97 to 0.78 using SSPNN. According to the matrix of Shapiro and Senapathy (1987) the T at position 76 has a frequency of 0.34 (the highest score at that position is for C: 0.51); G has the lowest frequency at that position (0.04). This single nucleotide change can aect binding of essential splicing factors such as U2AF 65 , which directly contacts the polypyrimidine tract (Zamore et al., 1992) . U2AF 65 is the large subunit of the U2 small nuclear ribonucleoprotein particle (snRNP) auxiliary factor (AF). U2AF is a prerequisite for the association of the U2 snRNP with the lariat branch point region during assembly of the spliceosome (Singh et al., 1995) .
Semi-quantitative fragment analysis showed the presence of three major isoforms at the 5' end of the BRCA1 gene: BRCA1-D22ntex5, BRCA1-D5 and the full length transcript (BRCA1-ex5FL). Real-time RT ± PCR was used to accurately quantify the three dierent transcripts in EBV cell lines of control persons and patients carrying the mutations IVS5+3A4G or IVS376T4G, and in freshly prepared leukocytes from healthy control individuals. Boundary spanning primers were designed that speci®cally recognize and amplify each splice variant ( Figure 2) .
We calculated the ratios of the alternative transcripts to the sum of all three isoforms, taken as an approximation for the total BRCA1 transcript level, and showed that these ratios were similar in RNAs extracted from EBV cell lines and freshly prepared leukocytes from control persons (Table 1) . However, in carriers of IVS5+3A4G the ratio of the BRCA1-D22ntex5 transcript is more than 10-fold increased compared to EBV cell lines from control persons (P50.001) and represents about half of the total BRCA1 transcript level. The eect of IVS5+3A4G is double: it activates a cryptic donor site and decreases the splicing eciency of the intron containing mutation since the BRCA1-Dex5 ratio is higher in carriers of the mutation compared to non-carriers (P50.001) ( Table  1) . The exon recognition model explains this observation, since binding of components of the splicing 2 5 7 Figure 1 Semi-quantitative fragment analysis of RT ± PCR products spanning exons 2 ± 7 revealed the presence of the same alternative transcripts in patients carrying IVS3-6T4G or IVS5+3A4G and in lymphocytes of control persons, but at dierent ratios (IM=internal marker Figure 2 Boundary spanning primers were designed that speci®cally recognize and amplify each splice variant (BRCA1-22ntex5 and BRCA1-~ex5) and the full length transcript (BRCA1-ex5FL) (numbering of the nucleotides according to the BRCA1 cDNA sequence (GenBank accession #U37574)). Primers were designed using PrimerExpress 1.5 software (Applied Biosystems). Ampli®cation speci®city was con®rmed using speci®c plasmids as template. Ampli®cation reactions and generation of absolute standard curves were performed as described by Vandenbroucke et al. (2001) BRCA1 splice mutations increase alternative transcripts K Claes et al machinery at one end of the exon enhances recognition of the other end of the same exon (Berget, 1995) . Since genetic material from only one patient carrying IVS376T4G was available, we performed 3 independent total RNA extractions from the EBV cell line of this patient. The ratio of the BRCA1-D22ntex5 transcript to the total BRCA1 transcript level is similar as in control persons (P=0.348) (Table 1) . However, as already indicated by fragment analysis, IVS376T4G mainly results in an in frame skip of exon 5. We found that the ratio of the BRCA1-Dex5 transcript in this cell line was approximately ®vefold higher compared to control persons (P50.001), but still only represents 8.03%+1.14% of the total BRCA1 expression level (Table 1) . We propose that a delicate balance between dierent BRCA1 transcripts exists and that disruption of this balance predisposes to tumor formation. Maintenance of a proper ratio between the BRCA1 full length product and the alternative transcripts could be functionally relevant. A precedent for such a situation has already been described for WT1 where a splice variant product was a more potent tumor suppressor than the full length version (Kudoh et al., 1995) . More recently, Ge et al. (1999) recognized that changes in the pattern of alternative splicing of Bin1 in melanoma contribute to tumorigenesis and that this represents a dominant mechanism inhibiting tumor suppressor activity of wild-type Bin1. Furthermore, it has been hypothesized that truncated or mutant BRCA1 proteins can function as dominant inhibitors of full-length wild-type protein (Fan et al., 2001b) .
Unfortunately, tumor material and additional family members to study segregation of IVS376T4G with the disease, were not available, therefore we cannot completely rule out the possibility that IVS376T4G represents a modi®er which, in combination with a mutation in this or another gene, predisposes to breast cancer. Furthermore, still another (undetected) mutation in linkage disequilibrium with this variant may be the real cause for breast cancer predisposition in this family.
We compared the total BRCA1 expression level in mutation carriers and controls to ®nd out if the altered alternative transcript ratios in mutation carriers were due to increased expression of the isoforms or to reduced total BRCA1 expression levels or both. The sum of the three isoforms was taken as an approximation for the total BRCA1 transcript level. Accurate quantitative measurements of gene expression might be relevant since small changes of APC expression levels were recently shown to aect predisposition to tumorigenesis in familial adenomatous polyposis (Yan et al., 2001) .
For comparison of expression levels between dierent samples, accurate and reliable normalization is required. It was recently shown that at least three relatively stable control genes are necessary to level o inherent expression variation of so-called housekeeping genes (Vandesompele et al., 2002) . To compare BRCA1 transcription levels between dierent samples we used the geometric mean of the four most stable housekeeping genes in leukocytes as normalization factor. In blood the expression of BRCA1 was approximately twofold lower compared to the level in EBV cell lines (P50.001). It is hypothesized that upregulation of BRCA1 mRNA is related to EBV-immortalization. Between the dierent control EBV samples a higher level of variation for total BRCA1 expression was noticed (coecient of variation (CV)=42%) compared to the dierent control blood samples (CV=25%). Although the mean total BRCA1 expression level was slightly lower in mutation carriers than in controls (data not shown), no statistically signi®cant dierences were de®ned due to a high level of variation between the dierent RNA extractions. In order to study the expression variability in more detail, we measured the levels of BRCA1 mRNA in two control EBV cell lines at dierent time points after a change to fresh medium. The RNA extraction was done in duplicate at each time point. From the RNA extractions at the same time point we obtained highly reproducible results: mean CV 7.32% (CVs between 2.44% and 16.75%). However between the dierent time points, a high level of variability for the total BRCA1 transcription level was observed (data summarized in Table 2 and Figure  3 ). From these observations it is clear that the total BRCA1 mRNA quantity in cultured cell lines is altered by changing nutritional conditions and that precautions must be taken when comparing total expression levels in (cancer) cell lines. Similarly, rapid changes and oscillations for mRNA steady-state levels of NF1, another tumor suppressor gene, have been described in cultured human keratinocytes after restoration of optimal nutritional conditions (Pummi et al., 2000) . It is known that BRCA1 mRNA levels exhibit a cell Table 1 Abundance of alternative BRCA1 transcripts in EBV cell lines of controls and mutation carriers and freshly prepared normal leukocytes. The sum of the three transcripts (BRCA1-Dex5, BRCA1-D22ntex5 and BRCA1-ex5FL) was taken as an approximation for the total BRCA1 expression level. The amounts of the alternative transcripts are presented as ratios to the total BRCA1 transcript level. The Mann ± Whitney test was used to determine the P-value to evaluate if the means of two dierent groups dier statistically signi®cant.
One-tailed P-values 50.001 were considered to be statistically signi®cant cycle-dependent pattern: expression is low in cells arrested in G0 or early G1 and highest at the G1-S phase transition (Vaughn et al., 1996) . Gudas et al. (1996) found that BRCA1 mRNA levels are dramatically reduced in senescent normal human mammary epithelial cells. BRCA1 is particularly expressed in rapidly proliferating and dierentiating cells (Marquis et al., 1995) . We have also determined the BRCA1-D22ntex5 and BRCA1-Dex5 transcript ratios in the RNAs extracted at the successive time points from both control persons (Table 2 and Figure 3) . Between the dierent time points the level of variation was smaller than seen for the total expression level, indicating that nutritional conditions in cultured cell lines have a smaller in¯uence on alternative transcript ratios.
In order to explore the functional signi®cance of the alternative transcripts, their prevalence was measured in normal breast and ovarian tissues and in one ovarian and ®ve breast cancer cell lines. For every cell line at least two independent RNA extractions were performed. With respect to the frequency of exon 5 skipping, no statistically signi®cant dierences between the cancer cell lines and control EBV cell lines were observed (data Figure 3 (a) Real-time RT ± PCR quanti®ed¯uctuations in total BRCA1 expression level in cultured human EBV cell lines after a change to fresh medium. Total RNA was extracted from EBV cell lines of two control persons. The RNA extraction was done in duplicate at each time point. For each quanti®cation assay, samples were tested in duplicate. The average values obtained at each time point are shown for the two control persons. As described by Vandesompele et al. (manuscript submitted), total BRCA1 transcript levels were normalized to the geometric mean of the four most stable housekeeping genes in leukocytes: ubiquitin C (UBC), phospholipase A2 (YWHAZ), beta-2-microglobulin (B2M) and ribosomal protein L13a (RPL13A). (b and c) After a change to fresh medium, the ratios of the isoforms BRCA1-~ex5 (b) and BRCA1-~22ntex5 (c) show less variation between the dierent time points than observed for the total BRCA1 transcription level Average of two independent RNA extractions at the same time point Figure 4 Expression level of the isoform BRCA1-~22ntex5 as a ratio to the total BRCA1 transcript level in EBV cell lines and fresh leukocytes from controls; in two normal breast tissues and ®ve breast cancer cell lines (HCC1937, T47D, BT20, MCF7, BT474); and in normal ovarian tissue and an ovarian cancer cell line (H1345-H134). Tissues were obtained as RNA samples from Clontech and Invitrogen (breast) or Ambion (ovary). The breast cancer cell lines (HCC1937, T47D, BT20, MCF7, BT474) were obtained from American Type Culture Collection and the ovarian cancer cell line (H1345-H134) was a kind gift from Dr C De Potter not shown). The BRCA1-D22ntex5 ratio in the cell lines is presented in Figure 4 . In normal breast tissue this transcript represents a fraction of 9.52+2.71% (based on RNA from two dierent samples), about the double of what is found in lymphocytes of control persons. In the breast cancer cell lines BT474, T47D, BT20 and MCF7 the transcript BRCA1-D22ntex5 is more abundant than in EBV cell lines of controls. In HCC-1937, a breast cancer cell line lacking endogeneous functional BRCA1 (Tomlinson et al., 1998) , the ratio is comparable with the ratio seen in EBV cell lines of controls. The highest ratio for the BRCA1-D22ntex5 mRNA was obtained in the ovarian cancer cell line H1345-H134. Laser capture microdissection studies will be performed in order to study the prevalence of both alternative transcripts in additional normal and pathological (breast, ovarian and other) cells. Deletion of the last 22 nucleotides of exon 5 creates a premature stop codon (Stop 64), but the highly conserved and functionally important amino-terminal BRCA1 RING ®nger motif (encompassing residues 24 ± 64) is maintained within this transcript. This RING ®nger domain interacts with several proteins (reviewed in: Welcsh and King (2001)). Fan et al. (2001a) showed that the amino-terminal of BRCA1 associates in vivo and binds in vitro the carboxyl-terminal domain of estrogen receptor a (ERa), by an estrogen independent interaction. For the ®ve tested breast cancer cell lines we found no relationship between the estrogen recepor status and the BRCA1-D22ntex5 transcript ratio. However, we cannot rule out a quantitative eect on estrogen receptor positivity.
In conclusion, this study provides insights in the way how two mutations outside the highly conserved AG/ GT splice sites of BRCA1 exon 5 result in increased alternative transcript ratios. These are the ®rst data providing evidence that increased alternative transcript levels in the BRCA1 gene might be a dominant mechanism predisposing to breast and/or ovarian cancer. In future work it will be important to determine the prevalence of these alternative transcripts in normal and pathological cells derived from several tisues in order to determine their role in dierent stages of tumor development.
